期刊
TRENDS IN CARDIOVASCULAR MEDICINE
卷 18, 期 1, 页码 33-37出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tcm.2007.11.004
关键词
-
资金
- NHLBI NIH HHS [R01 HL063414-03, R01 HL063414-05A1, R01 HL063414-04, R01 HL063414-01, R01 HL057516-11, R01 HL057516-10, R01 HL057516, R01 HL080137, R01 HL080137-02, R01 HL077428, R01 HL080137-01A1, R01 HL057516-09, R01 HL077428-02, R01 HL063414-07, R01 HL063414-02, R01 HL063414-08, R01 HL077428-01A2, R01 HL063414-06, R01 HL063414] Funding Source: Medline
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063414, R01HL080137, R01HL077428, R01HL057516] Funding Source: NIH RePORTER
Endothelial progenitor cells (EPCs) are peripheral blood mononuclear cells that can differentiate into mature endothelial cells. Adult EPCs were first discovered in human peripheral blood in 1997. Since then, the potency of EPCs for cardiovascular regeneration has been demonstrated in several preclinical studies; and investigators are beginning to evaluate the therapeutic utility of EPCs in early-phase clinical trials. This review summarizes the progression of basic, preclinical, and clinical research into the potential use of EPC therapy for cardiovascular regeneration.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
